India Exchange Filings

Gufic Biosciences Q2 FY27 Investor Presentation

Gufic Biosciences Ltd submits Q2 and H1 FY27 investor presentation, reporting three observations from the Indore US FDA pre-approval inspection.

  • The three inspection observations are being addressed; the EU compliance report has been submitted and certification is awaited.
  • Q2 FY27 registrations and first orders were secured in Saudi Arabia and Chile.
  • Distribution expanded across five European countries through Gufic Ireland.
  • The presentation covers unaudited results for the quarter and half year ended September 30, 2026; financial figures were not provided in the source material.

Original Filing

This is an automated summary of a public document. Always check the original before relying on it.